Overview

Daily Versus Twice Per Day Tamsulosin for Ureteral Stent Symptoms

Status:
Enrolling by invitation
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A single-center prospective, randomized study to assess two different dosing regimens (0.4 mg QD vs. 0.4 mg BID) of tamsulosin for ureteral stent-related discomfort will be completed.
Phase:
Phase 4
Details
Lead Sponsor:
Gundersen Lutheran Medical Foundation
Treatments:
Tamsulosin